SNSoligenix, Inc. SNGX · NASDAQ
$0.35 -4.08% (-$0.01)
- Market cap
- $7.62M
- Enterprise value
- -$1.89M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -151.4%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.00
- Free float
- 95.4%
About the company
Soligenix, Inc. (SNGX) is a biopharmaceutical company that focuses on the development and commercialization of drug products for the treatment of a range of diseases, including rare diseases and serious medical conditions. The company specializes in utilizing biotechnology and pharmacology for the development of therapeutic solutions. Soligenix also emphasizes research and clinical trials to confirm the efficacy and safety of its products. Their therapeutic innovations have the potential to help patients suffering from challenging-to-treat conditions. Shares of Soligenix, Inc. (SNGX) can be an interesting choice for investors tracking the biopharmaceutical sector and the development of therapeutic treatments.
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher J. Schaber
Employees
14
Headquarters
Princeton
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $9.81M against $302.6K.
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number